Glenmark expands US ophthalmic portfolio with new glaucoma drug

USA—Indian pharmaceutical giant Glenmark Pharmaceuticals Inc. has broadened its U.S. market presence by introducing a new generic treatment for glaucoma.

The company, operating through its U.S. subsidiary, has launched its latest ophthalmic solution, Latanoprost 0.005% (0.05 mg/mL), designed to treat high intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

This new product is a significant addition to Glenmark’s growing portfolio in the ophthalmic segment, marking its fourth eye care product available in the United States.

According to the company’s statement, Latanoprost ophthalmic solution is both bioequivalent and therapeutically equivalent to Upjohn US LLC’s widely recognized Xalatan Ophthalmic Solution.

With this launch, patients and healthcare providers can expect similar efficacy and safety profiles as the reference drug, ensuring a reliable treatment option that is also cost-effective.

Glenmark’s move highlights its commitment to expanding accessible healthcare solutions across various therapeutic areas in the U.S. market.

By introducing more affordable generic alternatives, the company aims to meet growing market demands while increasing treatment options for patients requiring ophthalmic care.

This strategy aligns with Glenmark’s broader vision of making quality healthcare accessible and affordable to a diverse patient population.

Furthermore, the launch of this new product comes at a time when the market for glaucoma medications is robust.

IQVIA sales data indicate that the reference-listed drug, Xalatan Ophthalmic Solution 0.005%, achieved annual sales of approximately US$113.5 million for the 12 months ending in December 2024.

 This strong market performance highlights the substantial demand for effective glaucoma treatments and reinforces the potential impact of Glenmark’s new offering.

Marc Kikuchi, President and Business Head of North America at Glenmark Pharmaceuticals, expressed his enthusiasm about this launch.

He emphasized that the new Latanoprost Ophthalmic Solution not only strengthens the company’s position in the ophthalmic channel but also reflects its ongoing commitment to innovation and customer-focused healthcare solutions.

Beyond its advancements in ophthalmic treatments, Glenmark Pharmaceuticals operates in over 80 countries and maintains 11 manufacturing facilities across four continents.

Scrip 100 notes that the company’s impressive global footprint is further bolstered by its ranking among the top 100 biopharmaceutical companies.

In addition, Glenmark’s focus extends beyond pharmaceuticals; in 2023, it became the only Indian pharmaceutical company to have its greenhouse gas emission reduction targets approved by the Science Based Target initiative.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.